Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC) on October 6, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +5.10% | +13.01% | +192.04% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
219 GBX | +2.34% | +0.92% | 743M | ||
1.65 USD | +5.10% | +13.01% | 288M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+192.04% | 288M | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics submitted a non-binding proposal to acquire PureTech Health plc.